Immunotherapyin HematologicalMalignancies 2018
CUNEOMay 17-19, 2018
Organized by Prof. Massimo Massaia, SC Ematologia AO S. Croce e Carle, Cuneo, Italy and Centro Interdipartimentale di Ricerca in Biologia Molecolare (CIRBM), Torino, Italy
PROGRAM
1st Cuneo City Immunotherapy Conference (CCITC)
Centro Incontri
GENERAL INFORMATION Meeting Venue Provincia di Cuneo – Centro IncontriCorso Dante Alighieri 41 - 12100 Cuneo, ItalyPhone: +390171 445894
Italian CME Credits A request for Italian CME credits have been made as follows: - Provider Studio ER Congressi SRL: ID 828-219967. - n° 14 CME credits for physicians (disciplines: Hematology,
Oncology, Internal Medicine, Clinical Pathology) and biologists
- Educational objective: “guidelines-protocols-procedures”.
RegistrationOnline registration: www.ercongressi.it - Congressi 2018The registration is free and includes: conference kit, parteci-pation in the scientific sessions, attendance certificate, coffee breaks, lunch, slides of the meeting.
SCIENTIFIC SECRETARIATProf. Massimo MassaiaSC Ematologia - AO S. Croce e Carle Via Michele Coppino 26 - 12100 Cuneo, Italy Laboratorio di Immunologia dei Tumori del Sangue (LITS) Centro Interdipartimentale di Ricerca in Biologia Molecolare (CIRBM) Università degli Studi di TorinoE-mail: [email protected]
ORGANIZING SECRETARIAT Studio E.R. Congressi Via Marconi, 36 - 40122 Bologna, Italy Phone +39 051 4210559 - Fax +39 051 4210174E-mail: [email protected] www.ercongressi.it
SIE – Società Italiana di EmatologiaSIES - Società Italiana di Ematologia Sperimentale
GITMO – Gruppo Italiano Trapianto di Midollo OsseoFIL – Fondazione Italiana Linfomi
Comune di CuneoProvincia di Cuneo
AO S. Croce e Carle di CuneoUniversità di Torino
UNDER THE AUSPICES OF
Saturday, 19 May, 2018SESSION VII: IMMUNE LESSONS FROM ALLO-HSCT (Francesca Bonifazi - Bologna, Nicola Mordini - Cuneo)
09.00-09.20 Transplantation trends in Italy: outcome and complications (Francesca Bonifazi - Bologna)09.20-09.40 Alloreactivity of NK cells (Andrea Velardi - Perugia) 09.40-10.00 Exploiting NK-cell alloreactivity in AML (Antonio Curti - Bologna) 10.00-10.20 γδ T cells and more in HLA-haploidentical HSCT (Francesco Locatelli - Roma)10.20-10.40 Mesenchimal Stem Cells (Maria Ester Bernardo - Milano)10.40-11.00 Tolerance induction combining T-cell depletion and posttransplant cyclophosphamide in non-ablative haploidentical HSCT (Franco Aversa - Parma)11.00-11.10 Key Points (Franco Locatelli - Roma)11.10-11.40 Coffee break
SESSION VIII: TUMOR VACCINATION: WHERE WE STAND (Roberto Lemoli - Genova, Marco Merlano - Cuneo)
11.40-12.10 LECTURE: Novel approaches of active immune therapy (Anas Younes - New York - USA) 12.10-12.30 ALK+ lymphomas and beyond (Roberto Chiarle - Boston - Torino)12.30-12.50 Idiotypic vaccination: why we have failed 20 years ago (Massimo Massaia - Cuneo - Torino)12.50-13.10 Idiotypic vaccination: why we may succeed nowadays (Roberto Lemoli - Genova)13.10-13.20 Key Points (Roberto Lemoli - Genova)13.20-13.30 Goodbyes and meeting close (Massimo Massaia)
Thursday, May 17, 2018 10.00-14.15 Registration 14.15-14.30 Welcome and information (Massimo Massaia - Cuneo - Torino)
SESSION I: PASSIVE IMMUNOTHERAPY: TARGETING TUMOR CELLS (Mariella Grasso - Cuneo, Fabrizio Pane - Napoli)14.30-14.50 CD20 in lymphoma and chronic lymphocytic leukemia: groundwork and outlook (Umberto Vitolo - Torino)14.50-15.10 CD38 in myeloma and beyond: groundwork & outlook (Mario Boccadoro - Torino)15.10-15.30 CD123 in leukemia and beyond: groundwork & outlook (Giovanni Martinelli - Meldola - FC)15.30-15.50 In search of new markers in chronic lymphocytic leukemia and lymphoma (Gianluca Gaidano - Novara)15.50-16.00 Key Points (Fabrizio Pane - Napoli)16.00-16.30 Coffee break
SESSION II: PASSIVE IMMUNOTHERAPY: ANTIBODY-DRUG CONJUGATES (Davide Rapezzi - Cuneo , Armando Santoro - Rozzano - MI)16.30-16.50 CD22: Inotuzumab ozogamicin (Sabina Chiaretti - Roma)16.50-17.10 CD30: Brentuximab vedotin (Antonello Pinto - Napoli)17.10-17.30 CD33: Gemtuzumab ozogamicin (Filippo Gherlinzoni - Treviso) 17.30-17.50 CD79a: Polatuzumab vedotin (Massimo Martelli - Roma)17.50-18.00 Key Points (Armando Santoro - Rozzano - MI)18.00-18.30 LECTURE: Emerging targets in acute myeloid leukemia (Sergio Amadori - Roma)
Friday, May 18, 2018 SESSION III: PASSIVE IMMUNOTHERAPY: TARGETING THE TUMOR MICROENVIRONMENT (Margherita Bonferroni - Cuneo, Mario Luppi - Modena)
08.30-09.00 LECTURE: Tumor microenvironment in MM (Angelo Vacca - Bari)09.00-09.20 SLAMF7/CS1 (Nicola Giuliani - Parma)09.20-09.40 CD38: “on target” “off tumor” effects (Fabio Malavasi - Torino)09.40-10.00 The DARPIN bispecific molecule (Roberto Ria - Bari)10.00-10.20 Role of aminoacids degrading enzymes in lympho-proliferative disease (Francesco Di Raimondo - Catania)10.20-10.50 LECTURE: Deconstructing the molecular genetics of human cancer and its therapeutic implications
(Pier Paolo Pandolfi - Harvard - USA)10.50-11.00 Key Points (Mario Luppi - Modena)11.00-11.30 Coffee break
SESSION IV: PASSIVE IMMUNOTHERAPY: TARGETING THE IMMUNE MICROENVIRONMENT (Claudia Castellino - Cuneo, Michele Spina - Aviano - PN)
11.30-11.50 PDI/PDL1 blockade in Hodgkin lymphoma (Armando Santoro - Rozzano - MI)11.50-12.10 PDI/PDL1 blockade in non-Hodgkin lymphoma (Carmelo Carlo Stella - Milano)12.10-12.30 Mechanisms of resistance to ICP blockade (Barbara Castella - Torino - Cuneo)12.30-12.50 Targeting macrophages in amyloidosis (Giampaolo Merlini - Pavia)12.50-13.00 Key Points (Michele Spina - Aviano - PN)13.00-14.30 Lunch
SESSION V: ADOPTIVE IMMUNOTHERAPY: IN VIVO RECRUITMENT (Valter Gattei - Aviano - PN, Daniele Mattei - Cuneo)
14.30-14.50 Blinatumumab in ALL and beyond: groundwork and outlook (Renato Bassan - Mestre - VE)14.50-15.10 DART: groundwork and outlook (Giorgio Inghirami - New York - USA)15.10-15.30 STING pathway activators (Massimo Di Nicola - Milano)15.30-15.50 Radiation and abscopal effect: lessons from solid tumors (Andrea Filippi - Pavia)15.50-16.00 Key Points (Valter Gattei - Aviano - PN)16.00-16.30 Coffee break
SESSION VI: ADOPTIVE IMMUNOTHERAPY: EX-VIVO RECRUITMENT (Paolo Corradini - Milano, Roberto Sorasio - Cuneo)
16.30-16.50 BET (Alessandro Rambaldi - Bergamo)16.50-17.10 Chimeric T cells (Luca Vago - Milano)17.10-17.30 CAR-T (Attilio Bondanza - Milano)17.30-17.50 CD1-restricted T cells (Giulia Casorati - Milano)17.50-18.00 Key points (Paolo Corradini - Milano)
Thursday, May 17, 201810.00-14.15 Registration 14.15-14.30 Welcome and information (Massimo Massaia - Cuneo - Torino)
SESSION I: PASSIVE IMMUNOTHERAPY: TARGETING TUMOR CELLS(Mariella Grasso - Cuneo, Fabrizio Pane - Napoli)14.30-14.50 CD20 in lymphoma and chronic lymphocytic leukemia: groundwork and outlook
(Umberto Vitolo - Torino)14.50-15.10 CD38 in myeloma and beyond: groundwork & outlook (Mario Boccadoro - Torino)15.10-15.30 CD123 in leukemia and beyond: groundwork & outlook (Giovanni Martinelli - Meldola - FC)15.30-15.50 In search of new markers in chronic lymphocytic leukemia and lymphoma (Gianluca Gaidano - Novara)15.50-16.00 Key Points (Fabrizio Pane - Napoli)16.00-16.30 Coffee break
SESSION II: PASSIVE IMMUNOTHERAPY: ANTIBODY-DRUG CONJUGATES (Davide Rapezzi - Cuneo , Armando Santoro - Rozzano - MI)16.30-16.50 CD22: Inotuzumab ozogamicin (Sabina Chiaretti - Roma)16.50-17.10 CD30: Brentuximab vedotin (Antonello Pinto - Napoli)17.10-17.30 CD33: Gemtuzumab ozogamicin (Filippo Gherlinzoni - Treviso) 17.30-17.50 CD79a: Polatuzumab vedotin (Massimo Martelli - Roma)17.50-18.00 Key Points (Armando Santoro - Rozzano - MI)18.00-18.30 LECTURE: Emerging targets in acute myeloid leukemia (Sergio Amadori - Roma)
Friday, May 18, 2018 SESSION III: PASSIVE IMMUNOTHERAPY: TARGETING THE TUMOR MICROENVIRONMENT (Margherita Bonferroni - Cuneo, Mario Luppi - Modena)
08.30-09.00 LECTURE: Tumor microenvironment in MM (Angelo Vacca - Bari)09.00-09.20 SLAMF7/CS1 (Nicola Giuliani - Parma)09.20-09.40 CD38: “on target” “off tumor” effects (Fabio Malavasi - Torino)09.40-10.00 The DARPIN bispecific molecule (Roberto Ria - Bari)10.00-10.20 Role of aminoacids degrading enzymes in lympho-proliferative disease (Francesco Di Raimondo - Catania)10.20-10.50 LECTURE: Deconstructing the molecular genetics of human cancer and its therapeutic implications
(Pier Paolo Pandolfi - Harvard - USA)10.50-11.00 Key Points (Mario Luppi - Modena)11.00-11.30 Coffee break
SESSION IV: PASSIVE IMMUNOTHERAPY: TARGETING THE IMMUNE MICROENVIRONMENT (Claudia Castellino - Cuneo, Michele Spina - Aviano - PN)
11.30-11.50 PDI/PDL1 blockade in Hodgkin lymphoma (Armando Santoro - Rozzano - MI)11.50-12.10 PDI/PDL1 blockade in non-Hodgkin lymphoma (Carmelo Carlo Stella - Milano)12.10-12.30 Mechanisms of resistance to ICP blockade (Barbara Castella - Torino - Cuneo)12.30-12.50 Targeting macrophages in amyloidosis (Giampaolo Merlini - Pavia)12.50-13.00 Key Points (Michele Spina - Aviano - PN)13.00-14.30 Lunch
SESSION V: ADOPTIVE IMMUNOTHERAPY: IN VIVO RECRUITMENT (Valter Gattei - Aviano - PN, Daniele Mattei - Cuneo)
14.30-14.50 Blinatumumab in ALL and beyond: groundwork and outlook (Renato Bassan - Mestre - VE)14.50-15.10 DART: groundwork and outlook (Giorgio Inghirami - New York - USA)15.10-15.30 STING pathway activators (Massimo Di Nicola - Milano)15.30-15.50 Radiation and abscopal effect: lessons from solid tumors (Andrea Filippi - Pavia)15.50-16.00 Key Points (Valter Gattei - Aviano - PN)16.00-16.30 Coffee break
SESSION VI: ADOPTIVE IMMUNOTHERAPY: EX-VIVO RECRUITMENT(Paolo Corradini - Milano, Roberto Sorasio - Cuneo)
16.30-16.50 BET (Alessandro Rambaldi - Bergamo)16.50-17.10 Chimeric T cells (Luca Vago - Milano)17.10-17.30 CAR-T (Attilio Bondanza - Milano)17.30-17.50 CD1-restricted T cells (Giulia Casorati - Milano)17.50-18.00 Key points (Paolo Corradini - Milano)
Thursday, May 17, 201810.00-14.15 Registration 14.15-14.30 Welcome and information (Massimo Massaia - Cuneo - Torino)
SESSION I: PASSIVE IMMUNOTHERAPY: TARGETING TUMOR CELLS(Mariella Grasso - Cuneo, Fabrizio Pane - Napoli)14.30-14.50 CD20 in lymphoma and chronic lymphocytic leukemia: groundwork and outlook
(Umberto Vitolo - Torino)14.50-15.10 CD38 in myeloma and beyond: groundwork & outlook (Mario Boccadoro - Torino)15.10-15.30 CD123 in leukemia and beyond: groundwork & outlook (Giovanni Martinelli - Meldola - FC)15.30-15.50 In search of new markers in chronic lymphocytic leukemia and lymphoma (Gianluca Gaidano - Novara)15.50-16.00 Key Points (Fabrizio Pane - Napoli)16.00-16.30 Coffee break
SESSION II: PASSIVE IMMUNOTHERAPY: ANTIBODY-DRUG CONJUGATES (Davide Rapezzi - Cuneo , Armando Santoro - Rozzano - MI)16.30-16.50 CD22: Inotuzumab ozogamicin (Sabina Chiaretti - Roma)16.50-17.10 CD30: Brentuximab vedotin (Antonello Pinto - Napoli)17.10-17.30 CD33: Gemtuzumab ozogamicin (Filippo Gherlinzoni - Treviso) 17.30-17.50 CD79a: Polatuzumab vedotin (Massimo Martelli - Roma)17.50-18.00 Key Points (Armando Santoro - Rozzano - MI)18.00-18.30 LECTURE: Emerging targets in acute myeloid leukemia (Sergio Amadori - Roma)
Friday, May 18, 2018 SESSION III: PASSIVE IMMUNOTHERAPY: TARGETING THE TUMOR MICROENVIRONMENT (Margherita Bonferroni - Cuneo, Mario Luppi - Modena)
08.30-09.00 LECTURE: Tumor microenvironment in MM (Angelo Vacca - Bari)09.00-09.20 SLAMF7/CS1 (Nicola Giuliani - Parma)09.20-09.40 CD38: “on target” “off tumor” effects (Fabio Malavasi - Torino)09.40-10.00 The DARPIN bispecific molecule (Roberto Ria - Bari)10.00-10.20 Role of aminoacids degrading enzymes in lympho-proliferative disease (Francesco Di Raimondo - Catania)10.20-10.50 LECTURE: Deconstructing the molecular genetics of human cancer and its therapeutic implications
(Pier Paolo Pandolfi - Harvard - USA)10.50-11.00 Key Points (Mario Luppi - Modena)11.00-11.30 Coffee break
SESSION IV: PASSIVE IMMUNOTHERAPY: TARGETING THE IMMUNE MICROENVIRONMENT(Claudia Castellino - Cuneo, Michele Spina - Aviano - PN)
11.30-11.50 PDI/PDL1 blockade in Hodgkin lymphoma (Armando Santoro - Rozzano - MI)11.50-12.10 PDI/PDL1 blockade in non-Hodgkin lymphoma (Carmelo Carlo Stella - Milano)12.10-12.30 Mechanisms of resistance to ICP blockade (Barbara Castella - Torino - Cuneo)12.30-12.50 Targeting macrophages in amyloidosis (Giampaolo Merlini - Pavia)12.50-13.00 Key Points (Michele Spina - Aviano - PN)13.00-14.30 Lunch
SESSION V: ADOPTIVE IMMUNOTHERAPY: IN VIVO RECRUITMENT (Valter Gattei - Aviano - PN, Daniele Mattei - Cuneo)
14.30-14.50 Blinatumumab in ALL and beyond: groundwork and outlook (Renato Bassan - Mestre - VE)14.50-15.10 DART: groundwork and outlook (Giorgio Inghirami - New York - USA)15.10-15.30 STING pathway activators (Massimo Di Nicola - Milano)15.30-15.50 Radiation and abscopal effect: lessons from solid tumors (Andrea Filippi - Pavia)15.50-16.00 Key Points (Valter Gattei - Aviano - PN)16.00-16.30 Coffee break
SESSION VI: ADOPTIVE IMMUNOTHERAPY: EX-VIVO RECRUITMENT (Paolo Corradini - Milano, Roberto Sorasio - Cuneo)
16.30-16.50 BET (Alessandro Rambaldi - Bergamo)16.50-17.10 Chimeric T cells (Luca Vago - Milano)17.10-17.30 CAR-T (Attilio Bondanza - Milano)17.30-17.50 CD1-restricted T cells (Giulia Casorati - Milano)17.50-18.00 Key points (Paolo Corradini - Milano)
Immunotherapyin HematologicalMalignancies 2018
CUNEOMay 17-19, 2018
Organized by Prof. Massimo Massaia, SC Ematologia AO S. Croce e Carle, Cuneo, Italy and Centro Interdipartimentale di Ricerca in Biologia Molecolare (CIRBM), Torino, Italy
PROGRAM
1st Cuneo City Immunotherapy Conference (CCITC)
Centro Incontri
GENERAL INFORMATION Meeting Venue Provincia di Cuneo – Centro IncontriCorso Dante Alighieri 41 - 12100 Cuneo, ItalyPhone: +390171 445894
Italian CME Credits A request for Italian CME credits have been made as follows: - Provider Studio ER Congressi SRL: ID 828-219967. - n° 14 CME credits for physicians (disciplines: Hematology,
Oncology, Internal Medicine, Clinical Pathology) and biologists
- Educational objective: “guidelines-protocols-procedures”.
RegistrationOnline registration: www.ercongressi.it - Congressi 2018The registration is free and includes: conference kit, parteci-pation in the scientific sessions, attendance certificate, coffee breaks, lunch, slides of the meeting.
SCIENTIFIC SECRETARIATProf. Massimo MassaiaSC Ematologia - AO S. Croce e Carle Via Michele Coppino 26 - 12100 Cuneo, Italy Laboratorio di Immunologia dei Tumori del Sangue (LITS) Centro Interdipartimentale di Ricerca in Biologia Molecolare (CIRBM) Università degli Studi di TorinoE-mail: [email protected]
ORGANIZING SECRETARIAT Studio E.R. Congressi Via Marconi, 36 - 40122 Bologna, Italy Phone +39 051 4210559 - Fax +39 051 4210174E-mail: [email protected] www.ercongressi.it
SIE – Società Italiana di EmatologiaSIES - Società Italiana di Ematologia Sperimentale
GITMO – Gruppo Italiano Trapianto di Midollo OsseoFIL – Fondazione Italiana Linfomi
Comune di CuneoProvincia di Cuneo
AO S. Croce e Carle di CuneoUniversità di Torino
UNDER THE AUSPICES OF
Saturday, 19 May, 2018SESSION VII: IMMUNE LESSONS FROM ALLO-HSCT (Francesca Bonifazi - Bologna, Nicola Mordini - Cuneo)
09.00-09.20 Transplantation trends in Italy: outcome and complications (Francesca Bonifazi - Bologna)09.20-09.40 Alloreactivity of NK cells (Andrea Velardi - Perugia) 09.40-10.00 Exploiting NK-cell alloreactivity in AML (Antonio Curti - Bologna) 10.00-10.20 γδ T cells and more in HLA-haploidentical HSCT (Franco Locatelli - Roma)10.20-10.40 Mesenchimal Stem Cells (Maria Ester Bernardo - Milano)10.40-11.00 Tolerance induction combining T-cell depletion and posttransplant cyclophosphamide in non-ablative haploidentical HSCT (Franco Aversa - Parma)11.00-11.10 Key Points (Franco Locatelli - Roma)11.10-11.40 Coffee break
SESSION VIII: TUMOR VACCINATION: WHERE WE STAND (Roberto Lemoli - Genova, Marco Merlano - Cuneo)
11.40-12.10 LECTURE: Novel approaches of active immune therapy (Anas Younes - New York - USA) 12.10-12.30 ALK+ lymphomas and beyond (Roberto Chiarle - Boston - Torino)12.30-12.50 Idiotypic vaccination: why we have failed 20 years ago (Massimo Massaia - Cuneo - Torino)12.50-13.10 Idiotypic vaccination: why we may succeed nowadays (Roberto Lemoli - Genova)13.10-13.20 Key Points (Roberto Lemoli - Genova)13.20-13.30 Goodbyes and meeting close (Massimo Massaia)
SIE Società Italiana di Ematologia
Immunotherapyin HematologicalMalignancies 2018
CUNEOMay 17-19, 2018
Organized by Prof. Massimo Massaia, SC Ematologia AO S. Croce e Carle, Cuneo, Italy and Centro Interdipartimentale di Ricerca in Biologia Molecolare (CIRBM), Torino, Italy
PROGRAM
1st Cuneo City Immunotherapy Conference (CCITC)
Centro Incontri
GENERAL INFORMATION Meeting Venue Provincia di Cuneo – Centro IncontriCorso Dante Alighieri 41 - 12100 Cuneo, ItalyPhone: +390171 445894
Italian CME Credits A request for Italian CME credits have been made as follows: - Provider Studio ER Congressi SRL: ID 828-219967. - n° 14 CME credits for physicians (disciplines: Hematology,
Oncology, Internal Medicine, Clinical Pathology) and biologists
- Educational objective: “guidelines-protocols-procedures”.
RegistrationOnline registration: www.ercongressi.it - Congressi 2018The registration is free and includes: conference kit, parteci-pation in the scientific sessions, attendance certificate, coffee breaks, lunch, slides of the meeting.
SCIENTIFIC SECRETARIATProf. Massimo MassaiaSC Ematologia - AO S. Croce e Carle Via Michele Coppino 26 - 12100 Cuneo, Italy Laboratorio di Immunologia dei Tumori del Sangue (LITS) Centro Interdipartimentale di Ricerca in Biologia Molecolare (CIRBM) Università degli Studi di TorinoE-mail: [email protected]
ORGANIZING SECRETARIAT Studio E.R. Congressi Via Marconi, 36 - 40122 Bologna, Italy Phone +39 051 4210559 - Fax +39 051 4210174E-mail: [email protected] www.ercongressi.it
SIE – Società Italiana di EmatologiaSIES - Società Italiana di Ematologia Sperimentale
GITMO – Gruppo Italiano Trapianto di Midollo OsseoFIL – Fondazione Italiana Linfomi
Comune di CuneoProvincia di Cuneo
AO S. Croce e Carle di CuneoUniversità di Torino
UNDER THE AUSPICES OF
Saturday, 19 May, 2018SESSION VII: IMMUNE LESSONS FROM ALLO-HSCT (Francesca Bonifazi - Bologna, Nicola Mordini - Cuneo)
09.00-09.20 Transplantation trends in Italy: outcome and complications (Francesca Bonifazi - Bologna)09.20-09.40 Alloreactivity of NK cells (Andrea Velardi - Perugia) 09.40-10.00 Exploiting NK-cell alloreactivity in AML (Antonio Curti - Bologna) 10.00-10.20 γδ T cells and more in HLA-haploidentical HSCT (Francesco Locatelli - Roma)10.20-10.40 Mesenchimal Stem Cells (Maria Ester Bernardo - Milano)10.40-11.00 Tolerance induction combining T-cell depletion and posttransplant cyclophosphamide in non-ablative haploidentical HSCT (Franco Aversa - Parma)11.00-11.10 Key Points (Franco Locatelli - Roma)11.10-11.40 Coffee break
SESSION VIII: TUMOR VACCINATION: WHERE WE STAND (Roberto Lemoli - Genova, Marco Merlano - Cuneo)
11.40-12.10 LECTURE: Novel approaches of active immune therapy (Anas Younes - New York - USA) 12.10-12.30 ALK+ lymphomas and beyond (Roberto Chiarle - Boston - Torino)12.30-12.50 Idiotypic vaccination: why we have failed 20 years ago (Massimo Massaia - Cuneo - Torino)12.50-13.10 Idiotypic vaccination: why we may succeed nowadays (Roberto Lemoli - Genova)13.10-13.20 Key Points (Roberto Lemoli - Genova)13.20-13.30 Goodbyes and meeting close (Massimo Massaia)
SIE Società Italiana di Ematologia
![[Mordini] 3D Numerical Modeling RC Behavior](https://static.documents.pub/doc/80x56/577cba0e1a28aba7118d9696/mordini-3d-numerical-modeling-rc-behavior.jpg)
